Humanity’s battle against cancer has spanned over 4,000 years. Thanks to the tireless efforts of researchers around the world, we now understand cancer far more deeply than ever before—and innovative treatments have dramatically improved the chances of survival.
Yet even in this age of advanced medicine, one harsh reality remains unchanged: Late detection still limits treatment options. Many patients are forced to undergo aggressive therapies with severe side effects and overwhelming costs, placing a heavy burden not only on individuals and families but also on healthcare systems and society as a whole.

At Craif, we believe that the most effective way to address this challenge is through prevention and early detection. However, these measures remain vastly underutilized. To break through this inertia and save as many lives as possible, we have dedicated ourselves to the development of next-generation cancer diagnostics.

Our approach is unique: we focus not on blood, but on urine—a non-invasive, easy-to-collect sample that holds a surprisingly rich reservoir of cancer-derived molecular signals. Our research has demonstrated that urinary microRNA enables high-precision analysis and opens the door to detecting cancers such as pancreatic and lung, which are notoriously difficult to identify in early stages. These insights are grounded in extensive clinical validation, and our commitment to challenging conventional norms has been central to Craif’s technological breakthroughs.

Early cancer detection is a global imperative. We firmly believe that our technology can transform the future of healthcare worldwide. In fact, our microRNA-based diagnostic platform is already leading the global field of non-invasive cancer screening.

Craif will continue to expand our mission globally—with one goal in mind: to help people everywhere live healthier lives, for a lifetime.